Active Ingredient: Abatacept
Abatacept in combination with methotrexate is indicated for:
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
10 mg per kg of body weight
10 mg per kg of body weight once every 14 day(s)
To be administered as a 30-minute intravenous infusion at the dose specified in Table 1. Following the initial administration, abatacept should be given 2 and 4 weeks after the first infusion, then every 4 weeks thereafter.
| Body Weight of Patient | Dose | Number of Vials^b^ |
|---|---|---|
| < 60 kg | 500 mg | 2 |
| ≥ 60 kg to ≤ 100 kg | 750 mg | 3 |
| > 100 kg | 1,000 mg | 4 |
a Approximating 10 mg/kg.
b Each vial provides 250 mg of abatacept for administration.
No dose adjustment is required when used in combination with other DMARDs, corticosteroids, salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs), or analgesics.
To be administered as a 30-minute intravenous infusion.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
